IN191496B - - Google Patents

Info

Publication number
IN191496B
IN191496B IN1036DE1999A IN191496B IN 191496 B IN191496 B IN 191496B IN 1036DE1999 A IN1036DE1999 A IN 1036DE1999A IN 191496 B IN191496 B IN 191496B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Yatendra Kumar
Rakesh Kumar Arora
Kaptan Singh
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Priority to IN1036DE1999 priority Critical patent/IN191496B/en
Priority to PCT/IB2000/001024 priority patent/WO2001009143A1/en
Priority to AU58391/00A priority patent/AU5839100A/en
Priority to CN00812246A priority patent/CN1371381A/zh
Priority to BR0012865-1A priority patent/BR0012865A/pt
Priority to US10/048,354 priority patent/US6602999B1/en
Priority to JP2001513950A priority patent/JP2003506329A/ja
Priority to EP00944159A priority patent/EP1204667A4/en
Priority to ZA200200692A priority patent/ZA200200692B/en
Publication of IN191496B publication Critical patent/IN191496B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN1036DE1999 1999-07-30 1999-07-30 IN191496B (OSRAM)

Priority Applications (9)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30
PCT/IB2000/001024 WO2001009143A1 (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
AU58391/00A AU5839100A (en) 1999-07-30 2000-07-24 An improved amorphous form of cefpodoxime proxetil
CN00812246A CN1371381A (zh) 1999-07-30 2000-07-24 改进的无定形头孢泊肟酯
BR0012865-1A BR0012865A (pt) 1999-07-30 2000-07-24 Uma forma amorfa aperfeiçoada da proxetil cefpodoxima
US10/048,354 US6602999B1 (en) 1999-07-30 2000-07-24 Amorphous form of cefpodoxime proxetil
JP2001513950A JP2003506329A (ja) 1999-07-30 2000-07-24 セフポドキシメプロキセチルの改良アモルファス形態
EP00944159A EP1204667A4 (en) 1999-07-30 2000-07-24 AN IMPROVED AMORPHE FORM OF CEFPODOXIM PROXETIL
ZA200200692A ZA200200692B (en) 1999-07-30 2002-01-25 An improved amorphous form of cefpodoxime proxetil.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30

Publications (1)

Publication Number Publication Date
IN191496B true IN191496B (OSRAM) 2003-12-06

Family

ID=11092065

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1036DE1999 IN191496B (OSRAM) 1999-07-30 1999-07-30

Country Status (9)

Country Link
US (1) US6602999B1 (OSRAM)
EP (1) EP1204667A4 (OSRAM)
JP (1) JP2003506329A (OSRAM)
CN (1) CN1371381A (OSRAM)
AU (1) AU5839100A (OSRAM)
BR (1) BR0012865A (OSRAM)
IN (1) IN191496B (OSRAM)
WO (1) WO2001009143A1 (OSRAM)
ZA (1) ZA200200692B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT408226B (de) * 1999-05-05 2001-09-25 Biochemie Gmbh Kristalliner 7-(2-(2-formylaminothiazol-4-yl)-2
WO2002068429A1 (en) * 2001-02-27 2002-09-06 Ranbaxy Laboratories Limited Process for the preparation of cefpodoxime proxetil
KR20070054730A (ko) * 2004-10-18 2007-05-29 테바 파마슈티컬 인더스트리즈 리미티드 알콜 및 케톤 및/또는 에스테르의 혼합물인 유기 용매에아토르바스타틴 헤미-칼슘 염을 용해시키고 용매를제거하여 비결정형 아토르바스타틴 헤미-칼슘을 제조하는방법
CA2609296A1 (en) * 2005-05-16 2006-11-16 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising a cephalosporin
KR100840132B1 (ko) * 2007-04-17 2008-06-23 재단법인서울대학교산학협력재단 포화 액체 이산화탄소를 사용한 세포독심 프록세틸의 건조
AU2013316754A1 (en) * 2012-09-11 2015-04-30 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
EP4450130A3 (en) * 2012-09-11 2025-01-08 Medivation Prostate Therapeutics LLC Formulations of enzalutamide
CN107427530B (zh) 2015-03-06 2020-09-08 阿堤亚制药公司 用于HCV治疗的β-D-2’-脱氧-2’α-氟-2’-β-C-取代的-2-改性的-N6-取代的嘌呤核苷酸
WO2017046756A1 (en) * 2015-09-18 2017-03-23 Lupin Limited Proxetil and axetil esters of cefixime
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
WO2017193914A1 (zh) * 2016-05-09 2017-11-16 苏州科睿思制药有限公司 克立硼罗游离形式的晶型及其制备方法和用途
CA3026885A1 (en) * 2016-06-16 2017-12-21 Xenon Pharmaceuticals Inc. Solid state forms of spiro-oxindole compounds
EP3510021A1 (en) * 2016-09-06 2019-07-17 Indena S.p.A. Solid forms of ingenol 3-(3,5-diethylisoxazole-4-carboxylate) and method for preparing the same
CN109689672B (zh) 2016-09-07 2023-05-30 阿堤亚制药公司 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10336679B2 (en) * 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
GEP20227457B (en) 2017-02-01 2023-01-10 Atea Pharmaceuticals Inc Nucleotide hemi-sulfate salt for treatment of hepatitis c virus
US11053233B2 (en) * 2017-03-30 2021-07-06 Merck Patent Gmbh Solid form of (S)-[2-chloro-4-fluoro-5-(7-morpholin-4-yl-quinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)-methanol
LT3713919T (lt) * 2017-11-22 2023-10-10 Agios Pharmaceuticals, Inc. Kristalinės n-(4-(4-(ciklopropilmetil)piperazin-1-karbonil)fenil)chinolin-8- sulfonamido formos
KR20210003780A (ko) * 2018-04-05 2021-01-12 스미토모 다이니폰 파마 온콜로지, 인크. Axl 키나제 억제제 및 그의 용도
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法
CN110437259B (zh) * 2019-08-14 2021-12-07 中国药科大学 头孢泊肟酯柚皮素共无定形物及其制备方法
JP2022551439A (ja) * 2019-10-04 2022-12-09 スミトモ ファーマ オンコロジー， インコーポレイテッド Ａｘｌ阻害薬製剤
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
KR20240022574A (ko) 2021-06-17 2024-02-20 아테아 파마슈티컬즈, 인크. 유리한 항-hcv 조합 요법
JP7370029B1 (ja) 2022-05-23 2023-10-27 国立大学法人 名古屋工業大学 湿式紡糸法を用いて製造された綿形状の骨再生材料、及び湿式紡糸法を用いて綿形状の骨再生材料を製造する方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223153A (en) 1979-02-09 1980-09-16 Eli Lilly And Company Crystalline forms of N-2-(6-methoxy)benzothiazolyl N'-phenyl urea
IT1165253B (it) 1979-07-12 1987-04-22 Blasinachim Spa Procedimento di fabbricazione di acido chenodesossicolico cristallino puro
US4486425A (en) * 1980-09-30 1984-12-04 Sankyo Company Limited 7-[2-(2-Aminothiazol-4-yl)-2-(syn)-methoxyiminoacetamido]-3-methoxymethyl-3-cephem-4-carboxylates
YU44680B (en) 1982-07-30 1990-12-31 Glaxo Lab Ltd Process for obtaining very pure amorphous form of cephuroxim axetile
IL100091A (en) 1990-12-12 1998-08-16 Zeneca Ltd Pharmaceutical compositions containing a physical form of n-[4-[5-(cyclopentyloxycarbonyl)amino-1-methyl indol-3-yl-methyl]-2-methylbenzenesulpho-namide and process for their preparation
ES2215161T3 (es) * 1991-09-07 2004-10-01 Aventis Pharma Deutschland Gmbh Diastereoisomero del ester 1-(isopropoxicarboniloxi)-etilico del acido 3-cefem-4-carboxilico y procedimiento para su preparacion.
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
AT413383B (de) * 1998-01-09 2006-02-15 Sandoz Ag Verfahren zur isolierung eines diastereoisomerengemisches von cefpodoxim proxetil
KR100342943B1 (ko) * 1999-08-04 2002-07-02 민경윤 비결정질 세푸록심 악세틸 고형분산체, 이의 제조 방법 및 이를 포함하는 경구투여용 조성물

Also Published As

Publication number Publication date
WO2001009143A1 (en) 2001-02-08
ZA200200692B (en) 2003-05-28
CN1371381A (zh) 2002-09-25
US6602999B1 (en) 2003-08-05
EP1204667A4 (en) 2002-10-30
EP1204667A1 (en) 2002-05-15
AU5839100A (en) 2001-02-19
JP2003506329A (ja) 2003-02-18
BR0012865A (pt) 2002-07-09

Similar Documents

Publication Publication Date Title
BE2018C020I2 (OSRAM)
BE2015C057I2 (OSRAM)
BE2016C007I2 (OSRAM)
BE2015C018I2 (OSRAM)
BE2014C017I2 (OSRAM)
BE2013C051I2 (OSRAM)
BE2013C020I2 (OSRAM)
BE2013C015I2 (OSRAM)
BE2013C001I2 (OSRAM)
BE2012C036I2 (OSRAM)
BE2008C046I2 (OSRAM)
BE2010C011I2 (OSRAM)
JP2002507757A5 (OSRAM)
JP2002502043A5 (OSRAM)
JP2002521141A5 (OSRAM)
BE2008C047I2 (OSRAM)
BE2011C004I2 (OSRAM)
BRPI0001672A2 (OSRAM)
JP2000286458A5 (OSRAM)
BRPI0001542A2 (OSRAM)
JP2002525223A5 (OSRAM)
JP2002528905A5 (OSRAM)
BRPI0012675B8 (OSRAM)
JP2002526310A5 (OSRAM)
IN187487B (OSRAM)